We demonstrated that this differential response is not due to enhanced tumor cell-specific effects of in vivo mTOR inhibition but rather due to preservation of antigen-specific CD8 T-cell responses that are suppressed following MEK inhibition. Here, CD8A is linked to neoplasm.